Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1992 1
1996 1
1997 1
1999 1
2001 2
2002 1
2003 7
2004 3
2005 4
2006 2
2007 5
2008 8
2009 14
2010 10
2011 11
2012 10
2013 5
2014 5
2015 4
2016 2
2017 2
2019 2
2020 1
2021 1
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Araujo D, et al. Among authors: ivy p. Ann Oncol. 2023 Jan;34(1):48-60. doi: 10.1016/j.annonc.2022.09.158. Epub 2022 Sep 29. Ann Oncol. 2023. PMID: 36182023 Free article. Review.
Randomized phase II designs.
Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Rubinstein L, et al. Among authors: ivy p. Clin Cancer Res. 2009 Mar 15;15(6):1883-90. doi: 10.1158/1078-0432.CCR-08-2031. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276275 Free PMC article. Review.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Cecchini M, et al. Among authors: ivy p. Br J Cancer. 2024 Feb;130(3):476-482. doi: 10.1038/s41416-023-02534-1. Epub 2023 Dec 22. Br J Cancer. 2024. PMID: 38135713 Free PMC article. Clinical Trial.
Multidrug resistance.
Schneider E, Paul D, Ivy P, Cowan KH. Schneider E, et al. Among authors: ivy p. Cancer Chemother Biol Response Modif. 1999;18:152-77. Cancer Chemother Biol Response Modif. 1999. PMID: 10800482 Review. No abstract available.
Novel designs and end points for phase II clinical trials.
Adjei AA, Christian M, Ivy P. Adjei AA, et al. Among authors: ivy p. Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276272 Review.
Expanding access to early phase trials: the CATCH-UP.2020 experience.
Baranda JC, Diaz FJ, Rubinstein L, Shields AF, Dayyani F, Mehta A, Mehnert JM, Trent J, Mabaera R, Mooney M, Moscow JA, Doroshow J, Waters B, Ivy P, Gore SD, Thomas A. Baranda JC, et al. Among authors: ivy p. JNCI Cancer Spectr. 2023 Jan 3;7(1):pkac087. doi: 10.1093/jncics/pkac087. JNCI Cancer Spectr. 2023. PMID: 36525371 Free PMC article.
Oxaliplatin: a review of evolving concepts.
Mani S, Graham MA, Bregman DB, Ivy P, Chaney SG. Mani S, et al. Among authors: ivy p. Cancer Invest. 2002;20(2):246-63. doi: 10.1081/cnv-120001152. Cancer Invest. 2002. PMID: 11901545 Review. No abstract available.
94 results